
Throughout May, June And July, All Donations Made To Parasites Without Borders Will Be Matched By PWB And Donated To Foundation For International Medical Relief Of Children
November 13, 2024
Real-world Effectiveness of Nirmatrelvir-Ritonavir and Molnupiravir in Non-hospitalised Adults with Covid-19: A Population-based, Retrospective Cohort Study (sic) Cohort Study | Alleviation of COVID-19 Symptoms and Reduction in Healthcare Utilization Among High-Risk Patients Treated with Nirmatrelvir/Ritonavir (NMV/R): A Phase 3 Randomized Trial |
Post-acute Sequelae of SARS-CoV-2 Cardiovascular Symptoms are Associated with Trace-level Cytokines that Affect Cardiomyocyte Function
November 7, 2024
Symptoms Six Weeks After COVID-19 are Reduced Among US Health Care Personnel Receiving Additional Vaccine Doses During the Omicron Period, December 2021–April 2022 |
Microbial Dynamics and Pulmonary Immune Responses in COVID-19 Secondary Bacterial Pneumonia |
Long-Term Risk of Autoimmune and Autoinflammatory Connective Tissue Disorders Following COVID-19
October 31, 2024
Repeated COVID-19 mRNA-based Vaccination Contributes to SARS-CoV-2 Neutralizing Antibody Responses in the Mucosa |
SARS-CoV-2 XBB.1.5 mRNA Booster Vaccination Elicits Limited Mucosal Immunity | Risk for Facial Palsy after COVID-19 Vaccination, South Korea, 2021–2022 | Nirmatrelvir Plus Ritonavir Reduces COVID-19 Hospitalization and Prevents Long COVID in Adult Outpatients |
Time to Sustained Recovery Among Outpatients With COVID-19 Receiving Montelukast vs Placebo - The ACTIV-6 Randomized Clinical Trial | Clinical and Functional Assessment of SARS-CoV-2 Sequelae among Young Marines – A Panel Study
October 24, 2024
The Risk of SARS-CoV-2 Transmission in Community Indoor Settings |
Relative Effectiveness of the NVX-CoV2373 Vaccine Compared With the BNT162b2 Vaccine in Adolescents |
Viral and Symptom Rebound Following Anti-SARS-CoV-2 Monoclonal Antibody Therapy in a Randomized Placebo-controlled Trial |
The Importance of Including Long COVID Outcomes When Developing Novel Treatments for Acute COVID-19 | The Persistence of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) after SARS-CoV-2 Infection
October 17, 2024
Relative Effectiveness and Waning of a Third Dose of mRNA COVID-19 Vaccine in Medicare Beneficiaries |
Remdesivir-associated Survival Outcomes among Immunocompromised Patients Hospitalized for COVID-19 |
Remdesivir Effectiveness in Reducing the Risk of 30-day Readmission in Vulnerable Patients |
Measurement of Circulating Viral Antigens Post-SARS-CoV-2 Infection in a Multicohort Study | Driving Under the Cognitive Influence of COVID-19 | Long COVID Facts and Findings
October 10, 2024
The Platform Trial In COVID-19 Priming and BOOsting (PICOBOO) |
COVID-19 Is a Coronary Artery Disease Risk Equivalent and Exhibits a Genetic Interaction With ABO Blood Type | Quantitative Susceptibility Mapping at 7 T in COVID-19: Brainstem Effects and Outcome Associations
Situation Dashboards

World Health Organization (WHO)
Novel Coronavirus (COVID-19) Situation from World Health Organization (WHO)

Johns Hopkins University (JHU)
Coronavirus COVID-19 Global Cases by the Center for Systems Science and Engineering (CSSE) at JHU

COVID-19 in US and Canada
1Point3Acres Real-Time Coronavirus (COVID-19) Updates in US and Canada with Credible Sources

Genomic Epidemiology COVID-19
Genomic Epidemiology of (COVID-19) Maintained by the Nextstrain team, enabled by data from GISAID.